首页> 外文期刊>Journal of cellular and molecular medicine. >Ginsenoside Rg1 ameliorates diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress‐induced apoptosis in a streptozotocin‐induced diabetes rat model
【24h】

Ginsenoside Rg1 ameliorates diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress‐induced apoptosis in a streptozotocin‐induced diabetes rat model

机译:人参皂苷Rg1通过抑制链脲佐菌素诱导的糖尿病大鼠模型中的内质网应激诱导的细胞凋亡改善糖尿病性心肌病

获取原文
           

摘要

Ginsenoside Rg1 has been demonstrated to have cardiovascular protective effects. However, whether the cardioprotective effects of ginsenoside Rg1 are mediated by endoplasmic reticulum (ER) stress-induced apoptosis remain unclear. In this study, among 80 male Wistar rats, 15 rats were randomly selected as controls; the remaining 65 rats received a diet rich in fat and sugar content for 4?weeks, followed by intraperitoneal injection of streptozotocin (STZ, 40?mg/kg) to establish a diabetes model. Seven days after STZ injection, 10 rats were randomly selected as diabetic model (DM) controls, 45 eligible diabetic rats were randomized to three treatment groups and administered ginsenoside Rg1 in a dosage of 10, 15 or 20?mg/kg/day, respectively. After 12?weeks of treatment, rats were killed and serum samples obtained to determine cardiac troponin (cTn)-I. Myocardial tissues were harvested for morphological analysis to detect myocardial cell apoptosis, and to analyse protein expression of glucose-regulated protein 78 (GRP78), C/EBP homologous protein (CHOP), and Caspase-12. Treatment with ginsenoside Rg1 (10–20?mg/kg) significantly reduced serum cTnI levels compared with DM control group (all P
机译:人参皂苷Rg1已被证明具有心血管保护作用。然而,人参皂苷Rg1的心脏保护作用是否由内质网(ER)应激诱导的细胞凋亡尚不清楚。在这项研究中,从80只雄性Wistar大鼠中随机选择15只作为对照组。其余65只大鼠在4周内饮食富含脂肪和糖分,然后腹膜内注射链脲佐菌素(STZ,40?mg / kg)建立糖尿病模型。注射STZ后7天,随机选择10只大鼠作为糖尿病模型(DM)对照,将45只合格的糖尿病大鼠随机分为三个治疗组,并分别以10、15或20?mg / kg /天的剂量施用人参皂苷Rg1 。治疗12周后,处死大鼠并获得血清样品以确定心肌肌钙蛋白(cTn)-I。收获心肌组织用于形态分析以检测心肌细胞凋亡,并分析葡萄糖调节蛋白78(GRP78),C / EBP同源蛋白(CHOP)和Caspase-12的蛋白表达。与DM对照组相比,人参皂苷Rg1(10–20?mg / kg)治疗可显着降低血清cTnI水平(所有P

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号